EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma

Aleena Boby, Michelle M Dugan iD, Helana Ghali, Shaliz Aflatooni, Danielle K DePalo, Wenyi Fan, Jonathan S Zager iD

Cancer Control · 2024

DOI: 10.1177/10732748241297326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Control, 2024. Verfasst von Aleena Boby und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Hauptthemen laut MEDLINE: Melanoma, Extremities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing/line of therapy of ILI has not been defined. This study evaluates ILI as first-line, second-line, or third or later-line therapy.

Methods

A retrospective review included all patients with unresectable ITM who underwent ILI from 2006-2023.

Results

A total of 130 patients were identified, 61% female, median age of 71 (31-89) years. Median follow-up was 37.5 months. ILI was first-line therapy in 80% (n = 104), second-line in 15% (n = 19), and third or later-line in 5.4% (n = 7). Overall response rate (ORR) and complete response (CR) rates for ILI as any line of therapy were 74% and 41%, respectively. ORR for ILI as first, second, or third or later-line therapy were 78%, 63%, and 57%, respectively. CR rates for ILI as first, second, or third or later-line therapy were 42%, 37%, and 43%, respectively. There were no significant differences in ORR, progression-free survival (PFS), overall survival, or disease-free survival between therapy lines. Median PFS for ILI as first, second, or third or later-line therapy were 6.9, 5.4, and 18 months, respectively.

Conclusion

Patients responded well to ILI, whether or not they received previous therapies for unresectable ITM. First-line ILI appears to have a better ORR than later lines of ILI. Although sample size limited statistical significance, there was a 21% improvement in ORR when ILI was used as first-line vs third-line therapy, which is clinically meaningful. ILI is effective for unresectable melanoma ITM and can be used as salvage therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaExtremitiesHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overChemotherapy, Cancer, Regional PerfusionSkin NeoplasmsNeoplasm MetastasisTreatment Outcome

Stichwörter der Autor:innen

ITM melanomain-transit metastasesisolated limb infusionisolated limb infusion for in-transit melanomametastatic melanomaregional chemotherapytreatment line of therapy

Autor:innen und Institutionen

  • University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA, USA.
  • Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

ORCID-Profile: Michelle M Dugan, Jonathan S Zager

Zitieren

APA

Boby, A., Dugan, M. M., Ghali, H., Aflatooni, S., DePalo, D. K., Fan, W., & Zager, J. S. (2024). Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma. Cancer Control. https://doi.org/10.1177/10732748241297326

Vancouver

Boby A, Dugan MM, Ghali H, Aflatooni S, DePalo DK, Fan W, et al. Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma. Cancer Control. 2024. doi:10.1177/10732748241297326

BibTeX
@article{Boby2024,
  author = {Boby, Aleena and Dugan, Michelle M and Ghali, Helana and Aflatooni, Shaliz and DePalo, Danielle K and Fan, Wenyi and Zager, Jonathan S},
  title = {Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma},
  journal = {Cancer Control},
  year = {2024},
  doi = {10.1177/10732748241297326}
}
Kostenlos starten →